-
OMV-Based mRNA Vaccines for Personalized Tumor Immunity
2026-08-24
Li and colleagues developed genetically engineered outer membrane vesicles (OMVs) that rapidly capture sequence-tagged mRNA antigens and deliver them to dendritic cells. The platform combines RNA binding, lysosomal escape, and innate immune stimulation, producing tumor control, complete regression in a subset of mice, and durable immune memory.
-
LDN-193189 as a Precision BMP Signaling Probe
2026-08-24
Explore LDN-193189 as an ALK inhibitor and experimental pathway probe, with practical guidance for connecting BMP signaling, epithelial barrier assays, and genetically defined endosomal models. This article emphasizes assay interpretation, controls, and the limits of cross-domain inference.
-
Targeted Tea-Polyphenol Nanoparticles for AAA Therapy
2026-08-23
This 2025 study develops cRGD-functionalized tea polyphenol nanoparticles that deliver doxycycline selectively to abdominal aortic aneurysm lesions. By combining integrin αvβ3 targeting, reactive oxygen species-responsive release, antioxidant activity, and matrix metalloproteinase inhibition, the platform addresses several pathological drivers while reducing doxycycline-associated hepatic and renal toxicity.
-
Oseltamivir acid: Mechanism to Assay Design
2026-08-22
Oseltamivir acid is an influenza neuraminidase inhibitor best evaluated through a layered evidence strategy spanning enzyme activity, viral release, cellular phenotypes, and translational interpretation. This article connects assay design with humanized-mouse pharmacology while defining the limits of cross-species extrapolation.
-
Polystyrene Nanoplastics and Placental Ferroptosis
2026-08-22
This study identifies an NMNAT3-dependent cascade linking gestational polystyrene nanoplastic exposure to placental NAD+ depletion, mitochondrial dysfunction, ferritinophagy, and ferroptotic injury. Its integrated metabolomic, cellular, genetic, and intervention-based design provides a mechanistic framework for studying environmentally induced fetal growth restriction and testing metabolic rescue strategies.
-
Prochlorperazine: Bench-to-Protocol Research Guide
2026-08-21
Prochlorperazine connects dopamine D2 receptor pharmacology with practical workflows in melanoma research, antiviral screening, and antiemetic therapy. This guide translates its concentration-dependent cellular effects and an acute mountain sickness trial protocol into assay design, controls, and troubleshooting decisions.
-
DAPT (GSI-IX): From Pathway Tool to Translation
2026-08-20
A translational framework for using DAPT (GSI-IX) to connect γ-secretase biology, Notch signaling, epithelial cell fate, and disease-model decision-making.
-
NAD+ Workflows for Metabolic Stress Assays
2026-08-20
Use NAD+ as a controlled redox and enzyme-substrate variable when dissecting energy stress, autophagy, DNA damage signaling, and protein deacetylation. This guide translates the latest AMPK–ULK1 findings into practical assay matrices, sample-handling controls, and troubleshooting decisions without treating NAD+ as a universal autophagy activator.
-
AI-10-49: CBFβ-SMMHC Inhibitor Evidence
2026-08-19
AI-10-49 is a selective CBFβ-SMMHC inhibitor that disrupts the leukemia-associated fusion protein interaction with RUNX1. Reported cellular, chromatin, and mouse-model findings support its use in acute myeloid leukemia research, while product specifications define its formulation and storage boundaries.
-
Full-Length αvβ3 Integrin Cryo-EM Conformations
2026-08-19
This cryo-EM study maps full-length human αvβ3 integrin across six apo and five ligand-bound conformations, including five previously uncharacterized states. The resulting continuum model clarifies how inhibitors engage distinct receptor states and provides a structural basis for designing more selective integrin-targeted compounds.
-
SP2509: An Epigenetic Decision Framework for AML
2026-08-18
SP2509 is a Lysine-specific demethylase 1 antagonist that links LSD1 inhibition to chromatin, differentiation, and apoptosis readouts in acute myeloid leukemia research. This article presents a decision-oriented assay framework and explains how cross-cancer epigenetic evidence can improve experimental design without overstating translation.
-
Dacomitinib in Cancer Signaling Workflows
2026-08-18
Dacomitinib (PF-00299804) enables controlled studies of irreversible ErbB signaling blockade, sustained pathway suppression, cell-cycle effects, and apoptosis in resistant cancer models. This workflow-focused guide also shows how to evaluate a hypothesis linking pan-HER inhibition with METTL17-associated mitochondrial ferroptosis defenses without overstating evidence from colorectal cancer research.
-
L-Phenylephrine in α1A Signaling Workflows
2026-08-17
Build more interpretable cardiovascular, cardiomyocyte, and neural assays with L-Phenylephrine, an adrenergic α1A receptor agonist suited to controlled receptor-stimulation experiments. This guide connects receptor-selective workflows with sex-aware hypertension research while emphasizing controls, timing, solution stability, and translational limits.
-
Sulfo-Cy5 NHS Ester for Immune Assay Design
2026-08-17
Sulfo-Cy5 NHS ester enables aqueous amine labeling with far-red sensitivity and reduced dye–dye quenching. This article presents an assay-design framework linking fluorescent readouts to the immune-mechanistic findings of a metal-ion-chelating nanostructure study.
-
THBS1 in Laryngeal Cancer: Prognostic Insights
2026-08-16
An integrative study combined transcriptomic datasets, machine learning, survival analysis, immune-pathway profiling, and cell-based assays to identify THBS1 as a prognostic biomarker and potential therapeutic vulnerability in laryngeal cancer. The findings connect THBS1 expression with epithelial-to-mesenchymal transition, integrin signaling, lipid metabolism, immune suppression, and aggressive cellular behavior, while also highlighting the need for prospective validation.